OTLK Outlook Therapeutics, Inc. Stock Quote

OTLK [NASD]

Index	-	P/E	-	EPS (ttm)	-0.32	Insider Own	1.20%	Shs Outstand	188.16M	Perf Week	5.84%
Market Cap	340.36M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	-	Shs Float	130.85M	Perf Month	-6.86%
Income	-53.20M	PEG	-	EPS next Q	-0.06	Inst Own	12.10%	Short Float	8.16%	Perf Quarter	16.43%
Sales	-	P/S	-	EPS this Y	48.30%	Inst Trans	3.54%	Short Ratio	8.44	Perf Half Y	-16.41%
Book/sh	0.26	P/B	6.27	EPS next Y	66.70%	ROA	-118.50%	Target Price	7.17	Perf Year	-27.56%
Cash/sh	0.34	P/C	4.85	EPS next 5Y	-	ROE	-244.90%	52W Range	1.19 - 3.27	Perf YTD	19.85%
Dividend	-	P/FCF	-	EPS past 5Y	58.80%	ROI	-	52W High	-50.15%	Beta	0.83
Dividend %	-	Quick Ratio	3.90	Sales past 5Y	-	Gross Margin	-	52W Low	36.97%	ATR	0.10
Employees	9	Current Ratio	3.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.93	Volatility	6.55% 6.05%
Optionable	No	Debt/Eq	0.46	EPS Q/Q	35.30%	Profit Margin	-	Rel Volume	0.38	Prev Close	1.60
Shortable	Yes	LT Debt/Eq	0.20	Earnings	May 27 BMO	Payout	-	Avg Volume	1.27M	Price	1.63
Recom	2.00	SMA20	0.68%	SMA50	-8.20%	SMA200	-11.25%	Volume	479,891	Change	1.87%

Sep-11-19

Initiated

Ladenburg Thalmann

Buy

May-16-19

Initiated

Oppenheimer

Outperform

$12

Apr-22-19

Initiated

Ascendiant Capital Markets

Buy

May-13-22 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update GlobeNewswire +7.38%
May-10-22 08:35AM	Outlook Therapeutics to Participate in Retina World Congress 2022 GlobeNewswire
May-09-22 08:35AM	Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight GlobeNewswire -7.50%
May-04-22 12:02PM	Here's What Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Shareholder Ownership Structure Looks Like Simply Wall St.
Apr-22-22 08:05AM	BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics GlobeNewswire
Apr-05-22 08:05AM	Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit GlobeNewswire
Apr-04-22 07:45PM	Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt? Simply Wall St.
Mar-31-22 08:05AM	Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD GlobeNewswire -10.55%
Mar-03-22 08:05AM	Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access GlobeNewswire +5.29%
Feb-24-22 08:05AM	Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress GlobeNewswire +16.31%
Feb-16-22 10:59AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? Simply Wall St. +7.14%
Feb-14-22 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update GlobeNewswire
Feb-10-22 08:05AM	Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-08-22 08:05AM	Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations GlobeNewswire
Feb-02-22 05:38PM	KWB Wealth Buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate ... GuruFocus.com -6.71%
08:05AM	Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival GlobeNewswire
Jan-25-22 08:05AM	Outlook Therapeutics Provides a Corporate Update and Business Outlook GlobeNewswire
Jan-19-22 08:05AM	Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference GlobeNewswire
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th ACCESSWIRE
Jan-04-22 08:35AM	Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference GlobeNewswire
Dec-22-21 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update GlobeNewswire
Dec-15-21 08:05AM	Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia GlobeNewswire
Dec-09-21 08:05AM	Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress GlobeNewswire -6.29%
Nov-29-21 04:15PM	Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.11%
Nov-24-21 06:49AM	What Type Of Shareholders Make Up Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Share Registry? Simply Wall St. -18.59%
Nov-23-21 10:30PM	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million GlobeNewswire +5.41%
04:30PM	Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock GlobeNewswire
Nov-13-21 11:00AM	Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference GlobeNewswire
Nov-10-21 08:05AM	Outlook Therapeutics to Present at the Virtual Investor Roundtable Event GlobeNewswire
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th ACCESSWIRE
08:05AM	Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference GlobeNewswire
Nov-03-21 08:05AM	Outlook Therapeutics to Present at the [email protected] 2021 Conference Retina Showcases GlobeNewswire
Oct-15-21 08:41AM	11 Best Penny Stocks To Buy According To Hedge Funds Insider Monkey
Oct-12-21 12:00PM	Outlook Therapeutics Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab GlobeNewswire
Oct-07-21 08:05AM	Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting GlobeNewswire +6.70%
Oct-05-21 08:05AM	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase GlobeNewswire
Sep-28-21 08:05AM	Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial GlobeNewswire
Sep-21-21 08:05AM	Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference GlobeNewswire
Sep-13-21 08:05AM	Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference GlobeNewswire
Sep-08-21 08:05AM	Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-26-21 09:57AM	Outlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year Simply Wall St.
Aug-13-21 08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update GlobeNewswire -5.14%
Aug-11-21 08:05AM	Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference GlobeNewswire
Aug-03-21 05:34PM	Why Outlook Therapeutics Stock Surged Today Motley Fool +6.64%
07:06AM	Outlook Therapeutics Stock Soars on Positive Results for Eye Treatment TheStreet.com
06:00AM	Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD GlobeNewswire
Jul-07-21 08:05AM	Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer GlobeNewswire +5.79%
Jul-02-21 05:04AM	Does Outlook Therapeutics (NASDAQ:OTLK) Have A Healthy Balance Sheet? Simply Wall St.
Jun-14-21 08:05AM	Outlook Therapeutics Announces Inclusion in the Russell 2000® Index GlobeNewswire
Jun-08-21 08:05AM	Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial GlobeNewswire
May-27-21 08:05AM	Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010 GlobeNewswire
May-18-21 06:15AM	How Many Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Do Institutions Own? Simply Wall St.
May-14-21 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update GlobeNewswire +7.73%
May-12-21 08:05AM	Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021 GlobeNewswire
Mar-31-21 09:23AM	Outlook Therapeutics' Bevacizumab-vikg Shows Favorable Safety Profile In Retinal Disease Study Benzinga
08:05AM	Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Mar-23-21 04:49AM	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Is Expected To Breakeven In The Near Future Simply Wall St.
Mar-04-21 09:00AM	Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -9.95%
Feb-17-21 08:05AM	Outlook Therapeutics to Participate in Cantor Fitzgeralds Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021 GlobeNewswire -8.36%
Feb-16-21 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update GlobeNewswire +8.70%
Feb-11-21 08:05AM	Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA (bevacizumab-vikg) GlobeNewswire -6.16%
Feb-04-21 11:18AM	Outlook Therapeutics Raises $35M Via Equity To Support ONS-5010 US Application, Shares Spike Benzinga +21.77%
09:05AM	Outlook Therapeutics Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA (bevacizumab-vikg) Through Planned BLA Submission GlobeNewswire
Feb-02-21 04:05PM	Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal GlobeNewswire
Jan-28-21 11:59PM	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million GlobeNewswire
05:35PM	Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock GlobeNewswire
Jan-12-21 08:05AM	Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics ONS-5010/LYTENAVA (bevacizumab-vikg) GlobeNewswire
Jan-05-21 08:00AM	Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Dec-23-20 09:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Dec-07-20 08:04PM	Is OTLK A Good Stock To Buy Now? Insider Monkey
Dec-01-20 08:05AM	Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
Nov-19-20 08:05AM	Outlook Therapeutics Announces Creation of Global Retina Advisory Council GlobeNewswire +8.11%
Nov-11-20 09:05AM	Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA GlobeNewswire +9.18%
Nov-05-20 08:05AM	Outlook Therapeutics Secures $10 Million in Additional Working Capital GlobeNewswire +5.05%
Nov-03-20 08:35AM	Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA (bevacizumab-vikg) GlobeNewswire
Oct-22-20 08:00AM	Outlook Therapeutics to Present at the Virtual Investor KOL Roundtable GlobeNewswire
Oct-13-20 08:05AM	Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Oct-12-20 03:30PM	These 2 Penny Stocks Could See Outsized Gains, Says Oppenheimer TipRanks +15.86%
Oct-07-20 08:05AM	Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital GlobeNewswire
Sep-30-20 08:05AM	Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration GlobeNewswire +7.95%
Sep-08-20 08:05AM	Outlook Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-26-20 02:52PM	When Can We Expect A Profit From Outlook Therapeutics, Inc. (NASDAQ:OTLK)? Simply Wall St. -36.33%
08:05AM	Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA (bevacizumab-vikg) from NORSE 1 GlobeNewswire
Aug-14-20 08:05AM	Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Jul-17-20 08:05AM	Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jul-07-20 08:05AM	Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Jun-25-20 09:43AM	Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7% Zacks
08:05AM	Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jun-23-20 08:00AM	Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules GlobeNewswire -5.15%
Jun-17-20 08:05AM	Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Jun-11-20 08:05AM	Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire -13.44%
Jun-10-20 08:12PM	Is Outlook Therapeutics, Inc. (OTLK) A Good Stock To Buy? Insider Monkey
Jun-09-20 08:05AM	Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series GlobeNewswire -5.83%
Jun-03-20 08:05AM	Outlook Therapeutics Announces Closing of $16.0 Million Private Placement GlobeNewswire -10.08%
May-26-20 08:05AM	Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire +16.33%
May-20-20 08:39AM	Some Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) Estimates Simply Wall St.
May-15-20 08:00AM	Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Apr-21-20 08:05AM	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors GlobeNewswire -5.61%
Apr-16-20 09:16AM	Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6% Zacks +7.00%
Apr-15-20 08:35AM	Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit GlobeNewswire +7.58%

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILZINGER KURT J	Director	Mar 01	Buy	1.69	27,708	46,827	273,117	Mar 03 05:30 PM
HILZINGER KURT J	Director	Feb 28	Buy	1.60	6,000	9,600	245,409	Feb 28 05:57 PM
HILZINGER KURT J	Director	Feb 24	Buy	1.46	41,160	60,094	239,409	Feb 28 05:57 PM
HILZINGER KURT J	Director	Feb 23	Buy	1.44	79,535	114,530	198,249	Feb 23 05:42 PM
HILZINGER KURT J	Director	Feb 22	Buy	1.49	95,597	142,440	118,714	Feb 23 05:42 PM
TRENARY C RUSSELL III	CEO and President	Dec 06	Buy	1.39	25,000	34,750	35,000	Dec 06 05:27 PM
Dagnon Terry	Chief Operating Officer	Dec 06	Buy	1.38	25,201	34,777	1,163,058	Dec 06 05:26 PM
Dagnon Terry	Chief Operating Officer	Dec 03	Buy	1.42	10,000	14,200	1,137,857	Dec 03 04:32 PM
Evanson Jeff	Chief Commercial Officer	Dec 03	Buy	1.34	35,200	47,168	1,177,130	Dec 06 05:25 PM
Sukhtian Faisal Ghiath	Director	Dec 02	Buy	1.40	18,000	25,200	38,000	Dec 02 05:08 PM
Haddadin Yezan Munther	Director	Dec 02	Buy	1.39	10,000	13,900	30,000	Dec 02 05:09 PM
TRENARY C RUSSELL III	CEO and President	Dec 02	Buy	1.40	10,000	14,000	10,000	Dec 02 05:07 PM
Sukhtian Ghiath M.	Director	Nov 29	Buy	1.25	16,000,000	20,000,000	27,834,257	Dec 01 07:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience